At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 313 enrolled
Drug / intervention
B244 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
In Brief
A Phase 2 clinical trial evaluating B244 and Vehicle for Migraine. Completed, enrolled 313 participants across 22 sites.
Detailed Summary
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsVeristat, Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionJun 2019
Study CompletionJul 2019
TodayJul 2026
First PostedApr 5, 2018
Enrollment StartMar 30, 2018
Primary CompletionJun 17, 2019
Study CompletionJul 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.2 years ago
Interventions
B244biological
B244 Suspension
Vehiclebiological
Vehicle Suspension